A Phase 1/2a trial initiated in 2016 is evaluating the anti-tumor efficacy of BMS-986179, both as monotherapy and in combination with anti-PD-1 (nivolumab), across various solid tumors (NCT02754141). The gene discussed is PDCD1; the disease is neoplasm.